Highlights

  • JAGX down 94.9% YTD in 2025 against NASDAQ-100’s 20.1% rise.
  • Q3 revenue at USD 3.1m shows 3.5% sequential growth but flat y.o.y.
  • Stock hits multiple new lows with liquidity and volume trending down five years.

Jaguar Health’s (NASDAQ:JAGX) share price closed at USD 1.28 at the end of November 2025. The stock is down USD 23.97 year-to-date. This reflects a 94.9% fall in 2025. The NASDAQ-100 Index has risen 20.1% in the same period. The relative price change stands at -115%. Jaguar Health ranks as the 299th largest biotechnology company on the NASDAQ by market cap.

Market cap now sits at USD 4.7m. It declined by USD 7.2m during the year. The stock is positioned within the bottom 3% of NASDAQ-listed names in 2025.

Price and Volume Trends

The stock fell 39% over the past month and 27.3% over the past quarter. Monthly price bands show a high of USD 2.13 and a low of USD 1.10 between late October and late November. VWAPs remain below prior months. Volume indices ranged from 0.6 to 2.2, with several days recording elevated turnover during price drops.

Long-term signals highlight persistent weakness. The stock hit new 52-week lows eight times in the past quarter. Relative strength over six months stands at the 5th percentile. Average daily trading volume has dropped 99.5% over five years.

Institutional Ownership

Institutional ownership reached 2.6% of issued capital at the end of Q3 2025. This increased from 0.3% at the end of 2024. The most recent SEC filing was on November 17, 2025.

Financial Performance: Q3 2025

Revenue for Q3 2025 was USD 3.1m. This marked a 3.5% rise from Q2 2025. It was down 0.8% compared with Q3 2024. EPS was -6.3 for the quarter. Net loss was USD 9.5m.
Sequential revenue improvement contrasts with year-over-year stagnation. Key financial indicators such as profitability, operating cash flow, and asset metrics remain under pressure.